Key facts
- Aro Biotherapeutics’s last known valuation is $181.5M (Nov 2023).
- It has raised $131.8M across 4 recorded rounds; the latest was Early Stage VC ($24.0M) in Dec 2022.
- Notable investors include Johnson & Johnson Innovation - JLABS, Johnson & Johnson JJDC, Ridgeback Capital, Avego Management, BVF Partners — 10 tracked in total.
- Aro Biotherapeutics has filed 7 Form Ds with the SEC since 2019, most recently Dec 2022 ($24.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Aro Biotherapeutics
Funding rounds
4 roundsAbout Aro Biotherapeutics
Developer of a protein drug platform designed to unlock the potential of genetic medicines. The company's drugs are small, non-antibody protein scaffolds that can be expressed as multi-specifics with therapeutic mechanisms of action for non-small cell lung cancer, enabling physicians to achieve efficacy and safety profiles for patients with cancer and other serious diseases.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2018
- Employees
- 49
- Website
- arobiotx.com/
- Ownership
- Privately Held (backing)
Aro Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aro Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aro Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.